top of page
About
Platform
Pipeline
News
Presentations & Publications
More
Use tab to navigate through the menu items.
Skyhawk Therapeutics Presents at Huntington's Disease Youth Organization HDYO International Congress 2025
Mar 17
1 min read
Skyhawk Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial
Dec 9, 2024
2 min read
Skyhawk Therapeutics to Present Preclinical Data of SKY-1214 Combination Treatment in Hematologic Cancers at the 66th American Society of Hematology Annual Meeting
Nov 21, 2024
2 min read
Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Oct 24, 2024
2 min read
Skyhawk Therapeutics to Present Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Oct 16, 2024
2 min read
Skyhawk Therapeutics to Present Additional Positive Topline Data from Parts A and B of Phase 1 Clinical Trial of SKY-0515 at European Huntington's Disease Network and Enroll-HD 2024
Sep 11, 2024
3 min read
Skyhawk Therapeutics Announces Positive Topline Results of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction
Jul 9, 2024
4 min read
Skyhawk Therapeutics Expands into State-of-the-Art Labs in its Basel, Switzerland Location
Jul 1, 2024
2 min read
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman
Jun 11, 2024
4 min read
Ipsen, Skyhawk ink deal worth up to $1.8B
Apr 22, 2024
1 min read
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Apr 22, 2024
2 min read
Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D
Apr 22, 2024
1 min read
Skyhawk Has Advanced to Multiple Ascending Dose in it’s SKY-0515 Huntington’s Trial
Mar 25, 2024
2 min read
Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small
Oct 23, 2023
3 min read
Drugging RNA
May 17, 2023
1 min read
Drugging RNA with Pills : Small Molecules for a Big Frontier
Sep 6, 2022
1 min read
Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets
Jul 6, 2022
2 min read
Bill Haney’s latest startup scores deal from Sanofi its newest Big Pharma partner, with $54M upfront
Jul 6, 2022
3 min read
Skyhawk Therapeutics Completes New Investment Round
Sep 14, 2021
1 min read
Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic
Sep 14, 2021
3 min read
bottom of page